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ABSTRACT
Introduction Humanitarian emergencies, of either natural 
or anthropogenic origins, are equivalent to major disasters, 
which can lead to population displacement, food insecurity 
and health system disruptions. Almost two- thirds of people 
affected by humanitarian emergencies inhabit malaria 
endemic regions, particularly the WHO African Region, 
which currently accounts for 93% and 94% of malaria 
cases and deaths, respectively. As of late 2020, the 
United Nations Refugee Agency estimates that there are 
globally 79.5 million forcibly displaced people, including 
45.7 million internally displaced people, 26 million 
refugees, 4.2 million asylum- seekers and 3.6 million 
Venezuelans displaced abroad.
Methods and analyses A systematic review and meta- 
analysis will be conducted to evaluate the impact of 
different vector control interventions on malaria disease 
burden during humanitarian emergencies. Published 
and grey literatures will be systematically retrieved from 
10 electronic databases and 3 clinical trials registries. 
A systematic approach to screening, reviewing and 
data extraction will be applied based on the Preferred 
Reporting Items for Systematic Reviews and Meta- Analysis 
guidelines. Two review authors will independently assess 
full- text copies of potentially relevant articles based on 
inclusion criteria. Included studies will be assessed for risk 
of bias according to Cochrane and certainty of evidence 
using the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) approach. Eligible 
studies with reported or measurable risk ratios or ORs with 
95% CIs will be included in a meta- analysis. Subgroup 
analyses, including per study design, emergency phase 
and primary mode of intervention, may be performed if 
substantial heterogeneity is encountered.
Ethics and dissemination Ethical approval is not 
required by the London School of Hygiene and Tropical 
Medicine to perform secondary analyses of existing 
anonymous data. Study findings will be disseminated 
via open- access publications in peer- reviewed journals, 
presentations to stakeholders and international policy 
makers, and will contribute to the latest WHO guidelines 
for malaria control during humanitarian emergencies.
PROSPERO registration number CRD42020214961.
INTRODUCTION
Malaria in humanitarian emergencies
Malaria is a life- threatening parasitic disease 
caused by Plasmodium species and transmitted 
by female Anopheles mosquitoes.1 In 2018, 
there were an estimated 228 million cases of 
malaria worldwide, including 405 000 deaths.1 
As defined by the WHO, a humanitarian 
emergency is a calamitous situation in which 
the functioning of a community or society is 
severely disrupted, causing human suffering 
and material loss that exceeds the affected 
population’s ability to cope using its own 
resources.2 Both natural (eg, earthquakes, 
floods or tsunamis) and anthropogenic (eg, 
violent political conflicts) hazards can lead 
to humanitarian emergencies, which may 
involve population displacement, food inse-
curity and disruptions to health systems; all 
of these factors contribute to excess mortality 
and morbidity among affected communities. 
While natural disasters may be short- lived, 
Strengths and limitations of this study
 ► This will be the first systematic review and meta- 
analysis of the impact of different vector control 
interventions on malaria disease burden during hu-
manitarian emergencies, providing a comprehensive 
global evidence summary that can be updated as 
new evidence emerges.
 ► Inclusion of a broad range of study types will allow 
the identification of studies from a diverse range of 
humanitarian contexts.
 ► By definition, humanitarian emergencies are unpre-
dictable and volatile and consequently, these set-
tings can be restrictive with respect to study design, 
limiting the number of community- level randomised 
control trials with epidemiological outcomes which 
can be considered in this review.
 ► Lack of a sensitive literature search strategy may 
result in a large number of titles and abstracts to 
screen initially.
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complex emergencies are often protracted, characterised 
by having complex social, political and economic origins, 
breakdown of governmental authority and infrastruc-
tures and often armed political conflict and human rights 
abuses.2 Globally, the United Nations Refugee Agency 
(UNHCR) currently estimates there are 79.5 million forc-
ibly displaced people3; with almost two- thirds of people 
affected by humanitarian emergencies inhabiting malaria 
endemic regions4 (figure 1).
Mass population displacement can increase the risk 
of epidemics and incidence of severe malaria, especially 
when immunologically naive individuals with little to no 
prior malaria exposure move to areas of more intense 
transmission. These populations are rendered vulnerable 
to epidemic malaria by their lack of protective immunity, 
increased concentration of people in exposed settings, 
inadequate health services, breakdown of national malaria 
control programmes, loss or emigration of skilled health-
care workers, insufficient access to effective treatment 
and control measures, food scarcity, and concomitant 
infections, malnutrition and anaemia.2 During human-
itarian emergencies, malaria morbidity and mortality 
can contribute to the breakdown of health services and 
local case management, which can both worsen and be a 
source of the emergency.
Humanitarian emergency features and settings
Humanitarian emergencies can be classified by their 
speed of onset, duration and setting, which all have impli-
cations for infectious disease control strategies (figure 2). 
Rapid- onset and slow- onset emergencies describe a 
sudden or gradual deteriorating situation, respectively, 
while protracted (chronic) emergencies involve consis-
tently high levels of humanitarian need. The criteria of 
the acute phase (phases 1 and 2 in figure 2) are elevated 
mortality rates, poor access to effective healthcare for 
the affected population, response needs that are beyond 
local or national capacity, and possible breakdown of 
normal coordination and response mechanisms. The 
post- acute phase (phase 3) includes a reduction in peak 
mortality rates and improved access to humanitarian aid 
and healthcare. The recovery phase (phase 4) is charac-
terised by the resumption of government, the withdrawal 
of humanitarian agencies and introduction of United 
Figure 1 Top: global map of internally displaced people 
(green) and refugee (red) populations, 2020. The UNHCR 
currently estimates that there are 79.5 million forcibly 
displaced people, including 45.7 million internally displaced 
people, 26 million refugees, 4.2 million asylum- seekers and 
3.6 million Venezuelans displaced abroad.3 Bottom: global 
map of Plasmodium falciparum parasite rate in children aged 
2–10 years, 2000–2017.54
Figure 2 Phases of sudden- onset, slow- onset or protracted (chronic) humanitarian emergencies. Time is indicated in days (D), 
weeks (W) and months (M). Adapted from World Health Organization.2
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Nations and non- governmental organisation (NGO) 
programmes and agencies. However, returning refugees 
may also re- integrate, bringing malaria with them, and 
depending on the level of strategic interest, this phase 
may or may not be neglected internationally. Protracted 
emergencies can remain entrenched in the post- acute/
early- recovery phases or cycle between acute and post- 
acute phases indefinitely.
Malaria vector control during humanitarian emergencies
During the acute phase of a humanitarian emergency, 
the first priorities for malaria control are effective case 
management, with prompt diagnosis and treatment.2 
Choice of vector control intervention will be determined 
by a number of key factors including, malaria infec-
tion risk and transmission dynamics, population demo-
graphics, prior malaria exposure, behaviour and mobility, 
vector species composition, vector feeding and resting 
preferences and emergency settings and infrastructure 
(table 1).
WHO recommended malaria control interventions, 
insecticide- treated nets (ITNs) and indoor residual 
spraying (IRS), are usually the first line preventative 
measures considered. Effective case management can be 
supplemented with long- lasting insecticidal net (LLIN) 
distributions, first targeting the most vulnerable popula-
tions (eg, pregnant women and children under-5 years 
old), with the goal of achieving and maintaining universal 
community- level coverage.5–19 IRS can be applied in well- 
organised, politically stable settings, such as transit camps, 
but is generally not feasible when dwellings are scat-
tered widely, of a temporary nature, or constructed with 
surfaces that are unsuitable for spraying.20 IRS may be 
more appropriate for protecting larger refugee popula-
tions in more compact and stable settings where housing 
is more permanent and structurally sound, and there is 
an absence of alternative resting sites.21–23 Targeted IRS 
can also supplement LLINs and be used together for 
insecticide resistance management.24 25
A suite of other community- level and personal vector 
control interventions has been designed for deployment 
during humanitarian emergencies, which will be consid-
ered in this review. One strategy has been to exploit utili-
tarian shelter materials, often provided in the early stages 
of emergencies, such as plastic sheeting, tarpaulins and 
tents, as mechanisms of insecticide delivery.26–29 Addi-
tional opportunities identified to apply insecticide among 
at- risk populations have included distributing insecticide 
treated bed sheets and blankets, clothing, hammocks and 
wall lining,30–38 and use of topical insecticides for human 
populations39–41 or to treat community livestock.42
Most interventions act by delivering a lethal dose of 
insecticide to the adult mosquito, protecting the host 
from exposure to a potentially infective bite. Some of 
these interventions, notably LLINs and IRS, may also 
have a community wide benefit (in areas of vector suscep-
tibility to the active ingredients), decreasing mosquito 
density and longevity, and ultimately interrupting malaria 
transmission. The insecticide used is dependent on 
the intervention and resistance profiles of local vector 
species.43 44 Other interventions, such as topical repel-
lents, work by preventing mosquitoes from detecting the 
host, by disrupting olfactory reception.45 These inter-
ventions only provide individual protection and do not 
impact vectorial capacity.43
There are multiple factors involved in ensuring a 
successful vector control programme during humani-
tarian emergencies. The intervention(s) selected must 
be feasible and consider local vector species, human 
resources, funding, logistics and population mobility.2 
Other benefits of vector control interventions, which may 
make them more acceptable to the user, include reducing 
flies in households and nuisance biting.46 and improved 
health and yields of treated livestock.42 Some interven-
tions may have low acceptability, for example, sleeping 
under an ITN or treated blanket/bedsheet in hot, 
humid conditions, some types of treated clothing may 




Level of endemicity; local transmission dynamics and stability; circulating Plasmodium species and 




Population origin and size; displacement dynamics and mobility; level of prior malaria exposure; 
proportion of vulnerable individuals (eg, pregnant women, children and the elderly); age and sex 
distributions; sleeping location and night- time behaviour; knowledge of malaria; education; healthcare 
and treatment seeking behaviour; prevalence of comorbidities (eg, malnutrition, anaemia, HIV); gender 




Local vector species composition; vector seasonality; host preference (anthropophillic/zoophillic); feeding 
time and location (early/late biting and indoor/outdoor biting); resting location (indoor/outdoor resting); 
level of insecticide resistance; flight range; breeding site preference
Emergency setting 
and infrastructure
Type of shelter or housing available (eg, ad- hoc refuse materials, plastic sheeting, tents, more permanent 
housing); road access and condition; camp or community organisation and layout; prior and present 
vector control interventions or programmes; timing of rainy seasons; potential to impact other vector- 
borne diseases (such as in areas of sympatric leishmaniasis) and nuisance insects (eg, lice, fleas, ticks, 
biting flies, bed bugs)
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be culturally inappropriate, topical repellents may cause 
irritation to individuals, and there may be a decrease 
in adherence over time to interventions which require 
sustained behavioural changes.40
Why it is important to do this review
To date, there has been insufficient, systematic syntheses 
of evidence for the WHO to make recommendations 
for deployment of malaria vector control interventions 
in humanitarian settings. While a number of aforemen-
tioned interventions have either been evaluated during 
or developed specifically for use in humanitarian emer-
gencies, the often unpredictable and volatile nature of 
these settings can often be restrictive in terms of designing 
experimental studies. Given these logistical constraints, 
a range of both observational and experimental study 
designs will be considered.
Objectives
This study aims to evaluate the impact of different vector 
control interventions on malaria disease burden during 
humanitarian emergencies.
Primary objective is
 ► To evaluate the impact of different vector control 
interventions on malaria disease burden during 
humanitarian emergencies.
Secondary objectives are
 ► To explore whether the impact of different vector 
control interventions varies with the phase of human-
itarian emergency (acute/post- acute, protracted and 
recovery/post- conflict phases).
 ► To explore whether the impact of different vector 
control interventions varies with the level of malaria 
transmission (low, <50% parasite rate in children; and 
high, >50% parasite rate in children).
 ► To explore whether the impact of different vector 
control interventions varies with the level of coverage 
during a humanitarian emergency.
METHODS AND ANALYSES
The following types of studies will be considered for inclu-
sion in this review:
 ► Cluster- randomised controlled trials (c- RCTs).
 ► Cluster- randomised cross- over studies.
 ► Cluster- randomised studies using a stepped- wedge 
design.
 ► Controlled before- and- after studies.
 ► Cohort studies (prospective or retrospective).
 ► Non- randomised cross- over studies.
 ► Programmatic evaluations.
 ► Cross- sectional studies.
 ► Case–control studies.
 ► Case series.
 ► Interrupted time series.
Experimental hut trials, other phase II studies or user 
acceptability surveys (including, quantitative knowl-
edge, attitude and practices questionnaires or qualitative 
observations, in- depth interviews and focus group discus-
sions) will be summarised descriptively.
Type of participants
Individuals of all age groups affected by humanitarian 
emergencies in malaria endemic regions; including those 
that have been internally displaced by humanitarian 
emergencies as well as host communities. A humani-
tarian emergency is defined as a calamitous situation, of 
either natural (including famine, flooding (localised or 
widespread), storms, cyclones, earthquakes, tsunamis) 
or anthropogenic origin (may include widespread (ie, 
affecting whole regions/countries) or geographically 
confined conflict (ie, affecting only parts of a country/or 
multiple countries, eg, the West African Islamic terrorist 
crisis affecting border regions of Mali, Niger, Nigeria, 
Burkina Faso, Cameroon and Chad), or persecution of a 
specific ethic group (eg, Bosnian, Rohingya and Rwanda 
genocides), in which the functioning of a community or 
society (whether a subsection or whole population) was 
severely disrupted, causing human suffering and mate-
rial loss that exceeded the affected population’s ability 
to cope using its own resources.2 Studies with military 
personnel or peacekeepers, in demilitarised zones, with 
migrant, tribal or nomadic populations or temporary/
seasonal labourers (eg, forest or dam workers, gold or 
gem miners) will be excluded.
Type of interventions
Any malaria- specific vector control intervention, which 
has been evaluated during a humanitarian emergency, 
will be considered for inclusion (table 2).
Type of outcome measures
To be eligible for inclusion, studies must report at least 
one of the following primary outcomes.
Primary outcomes
 ► Malaria case incidence: measured as number of cases 
per unit of time or the number of new uncomplicated 
malaria cases. We will use site- specific definitions as 
long as they have demonstrated (1) a fever or history 
of fever and (2) confirmed parasitaemia (by blood 
smear microscopy, rapid diagnostic test (RDT) or 
PCR).
 ► Malaria infection incidence: measured as count per 
person per unit of time or the number of new infec-
tions (individuals must have confirmed parasitaemia 
by blood smear, RDT or PCR).
 ► Parasite prevalence (clinical and subclinical malaria): 
the proportion of surveyed individuals with confirmed 
parasitaemia at the community- level.
Secondary outcomes
Epidemiological
 ► All- case mortality.
 ► Severe malaria, based on confirmed malaria diag-
nosis (individuals must have confirmed parasitaemia 
by blood smear, RDT or PCR) plus the presence of 
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clinical or laboratory features of vital organ dysfunc-
tion (these include impaired consciousness, coma, 
convulsions, respiratory distress, shock (systolic blood 
pressure <70 mm Hg in adults, <50 mm Hg in chil-
dren), jaundice, haemoglobinuria, hypoglycaemia, 
severe metabolic acidosis and anaemia).
 ► Anaemia prevalence as per WHO cut- offs, based on 
haemoglobin measurements taken in community 
surveys.
Entomological
 ► Entomological inoculation rate: the estimated number 
of bites by infectious mosquitoes per person per unit 
of time. This is calculated using the human biting rate 
(the number of mosquitoes biting an individual over a 
stated period, measured directly using human baits or 
indirectly using light traps, knock- down catches, entry 
or exit traps, baited huts or other methods of biting 
rate determination) multiplied by the sporozoite rate.
 ► Adult mosquito density: measured by a technique 
previously shown to be appropriate for the particular 
vector species (eg, human baits, light- traps, knock- 
down catches, entry or exit traps, baited huts or other 
methods).
 ► Sporozoite rate: measured as the number of caught 
adult mosquitoes positive for malaria sporozoites. 
Sporozoites can be detected through either molec-
ular or immunological methods.
Operational
 ► Intervention durability: measured by a technique 
previously shown to be appropriate, (eg, a time- series 
of WHO cone bioassays to monitor IRS residual 
activity or ITN/LLIN bioefficacy plus High Perfor-
mance Liquid Chromatography (HPLC) to deter-
mine intervention insecticidal content).
Adverse events
 ► Any indicators of adverse effects of the intervention, 
including the following:
 – Reports of toxicity to humans/animals.
 – Environmental impacts, such as changes to the bio-
diversity and ecosystem due to insecticidal use.
 – Changes to the levels of phenotypic/molecular 
insecticide resistance, assessed using standard 
WHO cylinder assays and/or Centers for Disease 
Control and Prevention bottle bioassays/molecular 
techniques.
 – Changes in mosquito species composition, for ex-
ample, species replacement or behaviour that re-
duces the efficacy of vector control interventions, 
for example, an increase in exophily, exophagy, 
zoophily or changes in biting time.
Unintended effects
 ► Impact on human behaviour, such as changes to indi-
viduals’ sleeping arrangements or use of other vector 
control interventions.
 ► Other vector- borne disease case incidence (eg, 
dengue and leishmaniasis).
Search methods for identification of studies
We will attempt to identify all relevant trials and studies, 
regardless of language, date or publication status 
(published, unpublished, in press and in progress).
Electronic searches
We will search the following databases: Cochrane Infec-
tious Disease Group Specialized Register; Central 
Register of Controlled Trials (CENTRAL), published in 
the Cochrane Library; MEDLINE (OvidSP); Africa- Wide 
Information (EBSCO); the WHO Global Index Medicus; 
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*Studies where the control group comprises no other insecticidal 
malaria vector control intervention will also be considered. Use 
of other vector control tools (in addition to the intervention under 
evaluation) must be balanced between study arms.
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the Science Citation Index Expanded (Web of Science); 
the Conference Proceedings Citation Index—Science 
(Web of Science); Embase (OvidSP); Global Health 
(CABI); and LILACS. We will also search the WHO Inter-
national Clinical Trials Registry Platform ( www. who. int/ 
ictrp/ search/ en),  ClinicalTrials. gov ( www. clinicaltrials. 
gov) and the ISRCTN registry ( www. isrctn. com) to iden-
tify ongoing trials.
Searching other resources
We will contact past and present personnel at key stake-
holders, donors, global policy makers, technical groups, 
NGOs, manufacturers, implementers and researchers in 
the field to identify sources of unpublished data. We will 
also check the reference lists of studies identified by the 
above methods.
Data collection and analysis
Selection of studies
Study selection will follow the Preferred Reporting Items 
for Systematic Reviews and Meta- Analysis (PRISMA) 
guidelines. Two review authors will independently assess 
the titles and abstracts of studies identified by the litera-
ture searches. These two review authors will assess full- text 
copies of potentially relevant articles based on inclusion 
criteria. Studies will be eligible for inclusion in the system-
atic review and meta- analysis if they satisfy all criteria: the 
study population consisted of individuals of either all 
age groups, or children of specified age groups (ie, <5 
years, >5–15 years), affected by humanitarian emergen-
cies (any phase) in malaria endemic regions; any malaria- 
specific vector control intervention was evaluated; and 
the primary outcome of interest was malaria infection 
risk, measured as case incidence, infection incidence 
or parasite prevalence. Studies will be eligible for inclu-
sion in secondary analyses, where none of the primary 
malaria risk indicators were measured, but at least one of 
the following secondary outcomes were reported: all- case 
mortality, severe malaria, anaemia prevalence, entomo-
logical inoculation rate, adult mosquito density, sporo-
zoite rate, intervention durability, occurrence of adverse 
events and user acceptability/usage.
We will compare the results of our assessments and 
resolve any disagreements by discussion and consensus, 
with arbitration by a third review author, if necessary. We 
will ensure that multiple publications of the same study 
are included once. We will list excluded studies, together 
with their reasons for exclusion, in a ‘Characteristics of 
excluded studies’ table; any highly relevant studies which 
did not meet the inclusion criteria, may be included in a 
separate annex. The results of the study selection process 
will be illustrated in a PRISMA diagram.
Data extraction and management
Two review authors will independently extract informa-
tion from the included studies into a pre- piloted data-
base, in which study settings, methods and results from 
identified studies will be recorded. Disagreements in data 
extraction will be resolved by discussion and consensus 
between the two review authors and arbitration by a third 
review author, if necessary. In case of missing data, we will 
contact the original study author(s) for clarification. Data 
will be extracted on the following:
 ► Lead author and publication year.
 ► Study period.
 ► Study design: type of study; method of participant 
selection (for c- RCTs: adjustment for clustering); 
cluster size; number of clusters; cross- over; sample 
size.
 ► Study participants: population size; origins and length 
of time in setting (with respect to the particular emer-
gency situation); characteristics: age, sex, ethnicity, 
recruitment rates, withdrawal, loss to follow- up, soci-
oeconomic status; levels of prior malaria exposure; 
proportion of vulnerable individuals; prevalence of 
comorbidities.
 ► Humanitarian emergency context: geographic 
country or area affected; underlying cause(s) of emer-
gency and relevant mitigating factors; structure and 
layout of residence area (eg, formal camp, informal 
settlement, open/closed); type of accommodation 
or housing available in study area; displacement 
dynamics and mobility; road access and condition; 
details of the political and logistical constraints 
encountered during different phases of humanitarian 
emergencies and their impact on the feasibility and 
choice of vector control intervention(s).
 ► Epidemiological context: malaria transmission inten-
sity; incidence; prevalence; Plasmodium species.
 ► Intervention: description of intervention (active 
ingredient, dose, formulation, intervention format, 
frequency and timing of implementation); coverage, 
usage and adherence; any reports of refusals and 
reasons why.
 ► Cointerventions: details of any other malaria or 
vector- specific control interventions (such as mass 
drug administration, active case detection, health 
education and untreated bednets); coverage and 
adherence; any reports of refusals and reasons why.
 ► Delivery mechanism(s): route of intervention deploy-
ment (eg, community- wide dissemination, health 
facility- based distributions, integration with other 
essential services); any additional information related 
to the method of implementation, including who 
implemented the intervention and who was targeted 
(the general population or a subpopulation).
 ► Outcome measurements: definition of outcome; diag-
nostic or surveillance method; passive or active case 
detection; duration of follow- up; time points at which 
outcomes were assessed; number of events; number 
of participants or unit time; statistical power; unit of 
analysis; incomplete outcomes/missing data.
 ► Other: primary and secondary vector(s) species; 
vector(s) behaviour (population seasonality, adult 
habitat, peaking biting times, exophilic/endophilic, 
exophagic/endophagic, anthropophilic/zoophilic); 
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method of vector collection(s); baseline measures of 
phenotypic insecticide resistance and any measures 
during the study period; baseline measures of geno-
typic insecticide resistance and any measure during 
the study period; any measure of vector sporozoite 
rate; identification of vector bloodmeal(s); vector 
parity and age structure; any measure of user accepta-
bility collected during the trial and reported by the 
treatment arm, including cross- sectional survey data 
of reported acceptability and qualitative data on opin-
ions about the intervention.
 ► Identification of major limitations in design, analysis, 
results, and any aspects that would limit generalisa-
bility of results.
 ► Source of funding of the study; reported conflicts of 
interest of authors.
For dichotomous outcomes, we will extract the number 
of participants experiencing each outcome and number 
of participants in each study group. For continuous 
outcomes, we will extract number of participants in each 
study group, the mean and a measure of variance (eg, 
SD or SE). For count/rate data outcomes, we will extract 
the number of outcomes in the treatment and control 
groups, and the total person time at risk in each group (or 
the rate ratio), and a measure of variance. For c- RCTs, we 
will record the number of clusters randomised, number 
of clusters analysed, measure of effect for example, risk 
ratio, OR or mean difference, with CIs or SDs, number 
of participants and the intracluster correlation coefficient 
(ICC) value. For non- randomised studies, we will extract 
adjusted measures of effects that attempt to control for 
confounding. If there are no adjusted measures reported, 
then we will extract unadjusted measures. We will group 
studies for analyses according to the intervention under 
evaluation.
Assessment of risk of bias in included studies
Two review authors will independently assess the risk 
of bias for each study, consulting a third review author 
if necessary. For c- RCTs, we will use the Cochrane ‘Risk 
of bias’ tool, as well as the six additional criteria listed 
in Section 23.1.2 of the Cochrane handbook for systematic 
reviews of interventions that relate specifically to c- RCTs.47 
For randomised cross- over trials, we will use the Cochrane 
‘Risk of bias’ tool, as well as the additional criteria listed 
in Section 23.2.3 of the Cochrane handbook for systematic 
reviews of interventions that relate specifically to randomised 
cross- over trials. For non- randomised controlled studies, 
we will use the Cochrane Effective Practice and Organisa-
tion of Care ‘Risk of bias’ tool. Biases will be classified as 
‘low’, ‘high’ or ‘unclear’ and summarised in graphs. For 
observational studies, we will use the Newcastle- Ottawa 
Scale .48 We will assess the risk of bias through a hier-
archy of domains, starting with ‘critical’, then ‘serious’, 
‘moderate’ and ‘low’. If any domain reaches critical risk 
of bias, then we will not continue with the assessment. We 
will make a risk of bias assessment for each outcome. If 
risk of bias is critical it will be excluded from the review. 
Highly relevant studies with a critical risk of bias may be 
included in a separate annex.
Measures of treatment effect
We will compare intervention and control data using 
(preferably) risk ratios or ORs if the outcome is dichot-
omous. For continuous data, we will present the mean 
difference (when studies use the same outcome measure-
ment scale, and Standardized mean difference (SMD) 
when studies use different outcome measurement scale); 
and for count/rate data, we will use rate ratios. We will 
use adjusted measures of effect to summarise treatment 
effects from non- randomised studies. We will present all 
results with their associated 95% CIs. We will report any 
accounts that signal adverse effects.
Unit of analysis issues
For c- RCTs, or non- randomised cluster trials, we will 
extract adjusted measures of effect where possible. If 
the study authors did not perform any adjustment for 
clustering, we will adjust the raw data ourselves using an 
ICC value. If an ICC is not reported, we will estimate 
this, with reference to similar studies, if possible. We will 
not present results from c- RCTs that are not adjusted 
for clustering. If we estimate the ICC, we will perform 
sensitivity analyses to investigate the robustness of our 
analyses. If we identify studies for inclusion that have 
multiple intervention arms, we will include data from 
these studies by either combining treatment arms, or by 
splitting the control group so that we only include these 
participants in the meta- analysis once. We will consider 
the level at which randomisation occurred, such as cross- 
over trials, c- RCTs, and multiple observations for the 
same outcome. For randomised cross- over trials, where 
neither carry- over nor period effects are identified as 
problematic, we will use a paired t- test for the analysis of 
continuous data from two- period, two- armed cross- over 
trials.
Dealing with missing data
In case of missing data, we will apply available- case anal-
ysis and will include data on known results, as well as 
‘non- adherent’ participants, excluded from the primary 
study authors’ analysis, but for whom data are avail-
able.49 ‘Non- adherent’ participant data may be included 
in ‘intention- to- treat’ or ‘as- treated’ analyses, as appro-
priate.49 The denominator will vary according to the total 
number of participants who had data recorded for the 
specific outcome as well as the total number of excluded 
participants included per analysis type. For outcomes 
with no missing data, we plan to perform analyses on an 
‘intention- to- treat’ basis. We will include all participants 
randomised to each group in the analyses and will analyse 
participants in the group to which they were randomised. 
If further data are needed, then the respective authors, 
companies or organisations will be contacted to obtain 
the missing data.
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Assessment of heterogeneity
Heterogeneity will be assessed by visually examining the 
overlap of study CIs, applying χ2 and I2 statistics. A χ2 test 
result with a p value <0.1 will indicate significant hetero-
geneity. Interpretation of I2 will follow the classification: 
30%– 60%: may represent moderate heterogeneity; 
50%–90%: substantial heterogeneity; 75%–100%: consid-
erable heterogeneity. If we observe substantial hetero-
geneity we will perform further subgroup analysis. If 
appropriate we will explore clinical and methodological 
heterogeneity through consideration of the trial popula-
tions, methods, and interventions and by visualisation of 
trial results.
Assessment of reporting biases
We will construct a funnel plot to assess reporting biases 
when performing an analysis of 10 or more studies. We 
will explore reasons for funnel plot asymmetry, including 
true heterogeneity of the effect with respect to trial size, 
poor methodological design (and hence bias of small 
trials), and publication bias, and will interpret results 
accordingly.
Data synthesis
We will analyse data using Review Manager 5.50 We will 
use fixed- effect meta- analysis to combine data if hetero-
geneity is absent. If considerable heterogeneity is present, 
we will combine data using random- effects meta- analysis 
and report an average treatment effect. We will decide 
whether to use fixed- effect or random- effects models 
based on the consideration of clinical and methodolog-
ical heterogeneity between trials.
Certainty of the evidence
We will assess the certainty of evidence using the GRADE 
approach.51 Evidence will start as high- certainty. However, 
if there is bias due to confounding, missing data or selec-
tion of the report result, outcomes will be marked as 
moderate, high or unclear risk of bias and the evidence 
will be rated down accordingly to low- certainty evidence.
For c- RCTs, we will rate each important outcome as 
described by.52 c- RCTs start as high quality evidence but 
can be downgraded if there are valid reasons within the 
following five categories: risk of bias, imprecision, inconsis-
tency, indirectness and publication bias. Non- randomised 
studies can also be upgraded if there is a large effect, 
and if all plausible residual confounding would reduce a 
demonstrated effect or would suggest a spurious effect if 
no effect was observed.52 We will summarise our findings 
in a ‘Summary of findings’ table.
We will summarise qualitative findings on consumer 
views for example, user acceptability narratively. If there 
are a sufficient number of included studies, two review 
authors will independently code the studies, and use 
thematic synthesis to identify themes and subthemes.
Subgroup analysis and investigation of heterogeneity
We will stratify the analysis by study design, phase of 
humanitarian emergency (acute/post- acute, protracted 
and recovery/post- conflict phases) and vector control 
intervention . Where substantial heterogeneity exists, we 
plan to perform the following subgroup analysis:
 ► Intervention coverage (appropriate levels to be deter-
mined with respect to the primary mode of action of 
each intervention, eg, community- wide mass effect vs 
personal protection).
 ► Participants (<5 years, pregnant women, adult, mixed 
age groups).
 ► Geographical region.
 ► Malaria vector species behaviour.
 ► Malaria transmission dynamics/seasonality.
Sensitivity analysis
We will perform sensitivity analysis on the primary 
outcome, to observe the effect of excluding trials at high 
risk of bias (for incomplete outcome data). If the ICC 
value is estimated, we will undertake sensitivity analyses to 
investigate the impact of varying the ICC value on meta- 
analysis results.
PATIENT AND PUBLIC INVOLVEMENT
No patients were involved in the design of this study.
ETHICS AND DISSEMINATION
This systematic review and meta- analysis will consist 
of secondary analyses of existing anonymous data and 
meets the criteria for waiver of ethics review by the 
London School of Hygiene and Tropical Medicine. As 
this research is based on previously published data, there 
will be no patient and public involvement in the design, 
interpretation or dissemination of study findings. This 
study protocol was drafted according to the PRISMA 
Protocols checklist.53 Any amendments to this protocol 
will be documented and published alongside the results 
of the systematic review and meta- analysis. Study find-
ings will be disseminated via open- access publications in 
peer- reviewed journals, presentations to stakeholders and 
relevant national and international policy makers and 
will contribute to the latest WHO guidelines for malaria 
control during humanitarian emergencies.
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